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Abstract:  
Background: To prevent onset of age-related diseases and physical and cognitive decline, 
interventions to slow human aging and extend health span must eventually be applied to people 
while they are still young and healthy. Yet most human aging research examines older adults, 
many with chronic disease, and little is known about aging in healthy young humans. Method: 
This article explains how this knowledge gap is a barrier to extending health span and puts 
forward the case that geroscience should invest in researching the pace of aging in young adults. 
As one illustrative example, we describe an initial effort to study the pace of aging in a young-
adult birth cohort by using repeated waves of biomarkers collected across the third and fourth 
decades to quantify the pace of coordinated physiological deterioration across multiple organ 
systems (e.g., pulmonary, periodontal, cardiovascular, renal, hepatic, metabolic, and immune 
function). Results: Findings provided proof of principle that it is possible to quantify individual 
variation in the pace of aging in young adults still free of age-related diseases. Conclusions: This 
article articulates research needs: to improve longitudinal measurement of the pace of aging in 
young people, to pinpoint factors that slow or speed the pace of aging, to compare pace of aging 
against genomic clocks, to explain slow-aging young adults, and to apply pace of aging in 
preventive clinical trials of anti-aging therapies. This article puts forward a research agenda to 
fill the knowledge gap concerning life-long causes of aging.  
Keywords: Longitudinal cohort study, Healthspan, Geroscience, Young adults 
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The longitudinal study of aging in human young-adults: 
Knowledge gap and research agenda 
 
 
The human lifespan has already been extended, and medical treatments save lives, but with the 
undesirable result that more people are living extra years with disability and dementia today than 
20 years ago [1].  If human aging could be slowed by anti-aging therapies, extra years of life 
could become extra years of health [2]. Anti-aging therapies show promise in animal-model 
research, and purportedly, some therapies are near-ready for translation to humans [3, 4]. It has 
recently been shown that interventions administered to healthy organisms can slow their 
aging[3]. Young adults are naturally the most attractive targets for therapies to extend health-
span because their organs are not yet damaged, making it possible in theory to prevent age-
related diseases[5]. Yet, most studies of human aging, including initial efforts at randomized 
trials of anti-aging therapies [6], examine older adults. As a result, very little is known about 
biological aging processes in young humans, a gap in knowledge that will retard translation from 
animal models to human clinical application. In this article, we suggest that in addition to 
studying seniors, the geroscience of health-span extension should also invest in studying 
processes of aging in young people.  
 
Studying aging as a lifelong process: A brief conceptual history. It is often remarked that 
“aging is a life-long process.” The innovative nature of studying aging in the context of the 
whole life course (including young people) can be illustrated by tracing the recent history of 
evolving conceptualizations of the connection between aging and disease (Figure 1). A 
dominant, prior conceptual model was that diseases such as heart disease, diabetes, cancer, and 
dementia onset in the latter half of the life course and subsequently converted individuals who 
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were cognitively and physically healthy into persons with disability and frailty, who died soon 
(top row of Figure 1). Under these assumptions, researchers recruited samples of older people, 
and focused on single diseases, with the aim of finding cures for them. Discoveries and 
treatments resulting from this research approach have demonstrably extended life expectancy, 
but left many patients with disability.  
 
 
 
Then, a newer conceptual approach ascended, based on the recognition that age-related diseases 
and mortality could be predicted from very early life, even antenatally (middle row of Figure 1). 
As examples, intrauterine growth retardation [7], low childhood intelligence [8], and childhood 
adverse experiences [9] were found to be early-life antecedents of late-life disease and mortality. 
New technology also enabled prediction of age-related diseases by genetic endowment present at 
the very beginning of life [10, 11]. Such discoveries about the importance of early-life factors for 
aging persuaded scientists that aging is a lifelong process that ought to be studied in young as 
well as old organisms [12]. Researchers began to envisage extending healthspan by 
implementing primary preventions and also to seek interventions to reverse early-life damage to 
health and cognition. But this conceptualization leaves an information vacuum between early-life 
risks and late-life disease onset.   
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Currently, new conceptual approaches are emerging to fill that vacuum. Now aging itself is 
considered a primary risk factor for nearly all age-related diseases [13, 14]. This idea makes it 
logically imperative to study aging as an antecedent to disease, and to do so requires measuring  
aging in healthy subjects in the first half of the life course before they develop age-related 
diseases (bottom row of Figure 1). The newer conceptual model accompanies research that 
measures, and manipulates, the pace of aging in young model organisms [3, 4, 15]. But 
translation of this newest conceptual approach to human research is still lagging. Thus, here we 
advocate a conceptual approach that looks harder at the first half of the human life course, 
specifically by quantifying the pace of aging in young adults, and by testing hypotheses about 
factors that bring about accelerated or slowed variation in young adults’ pace of aging (bottom 
row of Figure 1).  
 
Why is it important to study the pace of aging as a cause of disease? The 2013 NIH 
Advances-in-Geroscience conference concluded, “The major diseases causing morbidity and 
mortality have one root cause in common – aging” [16]. The hypothesis is that age-related 
chronic diseases are preceded by a gradual and interrelated loss of the body’s integrity that 
unfolds as a person’s chronological age increases. Consistent with this hypothesis, data from the 
Global Burden of Disease Project (http://www.healthdata.org/gbd, Institute for Health Metrics 
and Evaluation 2013) show increasing age is tightly linked to increasing morbidity from multiple 
chronic conditions affecting bodily systems, from the lungs to the brain [17]. Data like these 
imply that a key to extending healthspan is to slow aging itself [18, 19] because intervention to 
slow aging might be able to delay all age-related diseases simultaneously, rather than treating 
them one at a time [20].   
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Why is it important to measure the pace of aging in humans as well as in animals? Scientists 
have been able to quantify and manipulate the pace of aging in non-human model organisms in 
the laboratory, and announcements have been put forward that promising anti-aging therapies 
will soon be ready for human trials [3, 4]. But a fundamental obstacle blocks the translational 
pipeline: a lack of technology to measure the pace of aging in young humans. Human lifespans 
are long and chronic diseases of aging onset in the later decades of life. Thus, anti-aging 
interventions aiming to prevent disease will require decades of follow-up before outcomes of 
disease or mortality could be measured. Methods to measure the pace of aging in humans who 
have not yet developed chronic disease would make it possible to record and quantify pre-
treatment baseline, during-treatment change, and post-treatment outcome of participants in 
randomized clinical trials of rejuvenation therapies. But such measures are lacking [21]. 
 
Why is it important to study individual variation in the pace of human aging? The 
experimental science of extending animal lifespan has tended to ignore individual variation; this 
work has tended to study genetically identical animals living under uniform laboratory 
conditions and has focused on experimentally-induced variation as the variation of interest. But 
free-living humans are devilishly heterogeneous as compared to model organisms in the lab. A 
human adult’s pace of biological aging may be sped or slowed by genetic endowment, by 
varying early-life experience, and by individual differences in lifestyle. We think these factors 
must be researched and understood better because they will inevitably vex translation from 
preclinical healthspan models to humans [22]. Moreover, these factors include potential 
intervention targets that are uniquely human, and therefore are not easily investigated in animal 
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research, such as: perceptions and attributions, self-appraisal, purpose in life, personality traits, 
and mental disorders [23-26]. Measures of the pace of aging in young-adult humans are needed 
to provide a dependent outcome variable for investigations of how individual variation in the 
pace of aging is affected by genetics, early-life exposures, and adult lifestyle factors.   
 
Why is it important to study the pace of aging in young humans?  The emerging field of 
geroscience studies mechanisms of aging and causes of age-related disease with the aim to 
ultimately control aging and prevent disease [27]. Progress toward this aim is being constrained 
by research that solely examines human research participants in the last half of their lives. One 
reason for the focus on older adults in much geroscience research is that aging is often defined 
and quantified as the accumulation of age-related diseases and their complications. The result is 
that young people are typically excluded from aging research because they do not yet have an 
age-related disease. However, studying people who have age-related disease may not be the only 
or even the best way forward. Across all branches of medicine primary-prevention targets have 
been difficult to uncover by studying patients already diagnosed with diseases, in part because 
diseases are typically clinically diagnosed years after their etiology is well underway. We can 
think of at least three advantages to conducting geroscience research in young people.  
 
The first reason geroscience should exploit young people is that there is now evidence that the 
pathogenesis of age-related diseases involves gradually accumulating damage to organ systems, 
beginning in the first half of the life course [28-32]. Moreover, it is now known that potentially 
preventable risk exposures and causes of age-related disease begin in early childhood [33] . An 
important implication of this new knowledge is that future interventions will need to be 
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scheduled before midlife if they hope to prevent accelerated aging, pre-empt age-related disease, 
and improve the quality of longer lives [34]. In order to design such interventions, there is a lot 
to be learned about exactly how damage accumulates during the years between conception, 
childhood, and disease onset. Studying processes of aging in younger cohorts can provide valid 
prospective measures of exposures and the damage they cause to organ systems (including the 
brain), while etiological processes are unfolding.  
 
A second reason to take advantage of young cohorts is that scientists cannot assume that causes 
and correlates of problematic aging uncovered in studies of individuals over age 50 will also 
explain individual differences in the pace of aging in people under age 50. For example, genetic 
correlates in extreme-longevity samples have been found to differ from genetic correlates in 
older-adult samples [10]. Thus, studying the pace of aging in younger cohorts can answer the 
question of whether factors that influence aging in younger adults and older adults are the same 
or different.  
 
A third reason geroscientists should embrace young cohorts is to improve study designs, and 
reduce bias and noise in their data [11, 35]. Studying aging in the already-aged introduces 
selection bias. Many individuals with a fast pace of aging may not survive into their sixth or 
seventh decades of life, yielding missing data for the cases of greatest interest. Studying aging in 
individuals who already have chronic disease also introduces “noise” from disease symptoms, 
medication regimens, and treatment responses that interfere with the “signal” of basic processes 
of aging. Studying the pace of aging in younger cohorts can avoid these ubiquitous sources of 
bias and noise.  
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Cross-sectional approaches to measuring individual differences in biological age.  
Measuring biological aging is a recent enterprise [13], and there is no consensus yet about the 
best methods [36-38]. Candidate biomarkers of aging are numerous (e.g., telomere length, 
methylation profiles), but findings are mixed [21, 39-42]). (A biomarker is anything that can be 
used as a measureable indicator of a disease state or other physiological state of an organism.) As 
an alternative to single-marker aging indicators, multi-biomarker algorithms have been 
recommended as a way to achieve more reliable measurement [43-47]. As such, research groups 
are using data to identify multi-biomarker aggregates that correlate with participants’ 
chronological age and/or predict participants’ mortality better than does their chronological age.  
 
Most multi-biomarker composite measures proposed so far are designed for cross-sectional data. 
Such one-wave cross-sections have inherent limitations which render them unable to track aging 
as change within lives of individuals. First, they cannot disentangle aging-related change from 
other factors that influence biomarker levels, such as pre-existing poor health sustained since 
childhood, or an acute spell of illness around the time of data collection. Second, in samples 
where the participants vary in age but the biomarkers are all surveyed at one time-point, age-
differences in biomarker levels are not independent of cohort effects (e.g., historical 
improvements in health-related living conditions can make younger participants look better than 
older participants on biomarkers. Third, even if a cross-sectional algorithm predicts mortality 
well in a sample with age variation, its utility for quantification of aging in younger persons 
remains uncertain because most deaths observed during follow-up occur to a sample’s oldest 
participants. Finally, cross-sectional measures are static whereas aging is a dynamic process 
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sometimes referred to as “damage accrual”; one-wave indicators are unable to truly track 
whether a young person’s pace of age-related biological decline is actually accelerating or 
slowing down [48]  
 
A longitudinal approach to measuring the pace of biological aging. A novel approach is to 
study aging longitudinally, while tracking a cohort of young adults who are approaching the 
middle of the life course, a developmental period when individuals start to diverge in their aging 
trajectories, but before most diseases onset.  We are undertaking one such study, the Dunedin 
Study, which has followed a representative birth cohort 1037 individuals since their birth in 
1972-1973 and is now entering its fifth decade with 95% retention [49]. The cohort is primarily 
white, and it is population-representative; a lifetime of research participation has not improved 
Study members’ health as compared to the New Zealand National Health & Nutrition Survey 
(e.g. BMI, smoking, GP visits) [49]. Cohort members are largely still healthy; by age 40, only 11 
study members (1%) have been diagnosed with an age-related condition: heart attack, stroke, or 
type-2 diabetes. New Zealand is a useful laboratory because it suffers the same types of income 
inequalities found in the USA and the UK (GINI coefficient=0.34 for NZ vs 0.38 for the US, 
0.35 for the UK). Like the UK, NZ spends less on health care than the US (NZ=8% vs US=17% 
of GDP), but has a longer life expectancy (NZ=80.7 vs US=78.5 years), and has a national 
health-care system.  
 
Taking advantage of this longitudinal-cohort study, we developed a measure of the pace of 
aging. We designed the measure in accordance with contemporary geroscience theory about 
human aging as a gradual and inter-related loss of integrity in every organ system, beginning in 
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the first half of the life course [13, 14, 16, 20]. In the Dunedin Study, at three measurement 
occasions spanning 12 years, we repeatedly measured blood pressure, cardiorespiratory fitness, 
pulmonary function, periodontal disease, anthropometric indices, lipid parameters, glycated 
hemoglobin, indicators of kidney and liver function, and systemic inflammation, as well as 
telomere length. Of course, every biomarker has its own unique sources of individual variation at 
any specific point in time. Temporary sickness can spike a biomarker, and other sources of 
measurement error insert abnormal values into assay data. Our approach was designed to look 
beyond individual measurements to capture correlated trends among biomarkers as they changed 
with advancing chronological age. Our hypothesis was that if, for example, declining 
cardiorespiratory-fitness taps aging, then a research participant who showed declining 
cardiorespiratory-fitness on testing from time 1 to time 2 to time 3 should likewise show 
correlated decline in, for example, their kidney, lung, and immune function. Accordingly, we 
measured the pace of aging by assessing decline in a panel of biomarkers repeatedly collected. 
Biomarkers were assessed at ages 26, 32, and 38 years (and will be repeated at age 45 years in 
2017). The repeated-measures approach separates sources of variation. One source is baseline 
individual differences in physiology, which in part reflect poor health from earlier in life, and 
thus cannot unambiguously represent aging. Another source is acute change in a biomarker that 
recovers; again, not aging. The last source is physiological change over time in the direction of 
decline, as shown in many biomarkers from multiple organ systems simultaneously tracked over 
the same time period. According to geroscience theory, only the latter represents the pace of 
aging.  
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Each cohort member’s Pace of Aging was calculated from longitudinal analysis of the 18 
biomarkers (for details, see Belsky et al., 2015). Briefly, we used mixed-effects growth models 
to calculate each study member’s personal slope for each of the 18 biomarkers one by one and 
then computed each study member’s pace of aging as the sum of 18 slopes. Our analyses 
revealed four findings.  First, growth-curve models showed declining function in the biomarkers 
from ages 26-38 years (e.g., higher triglycerides, lower maximal aerobic capacity, higher blood 
pressure). Second, addressing the critical theoretical prediction, the “slopes” of change in the 
biomarkers were themselves positively inter-correlated, showing correlated age-related decline 
across multiple organ systems.  Third, the pace of this correlated biomarker decline varied 
among individuals; some cohort members declined faster than others. Fourth, sensitivity analyses 
showed that contrary to some expectations, the pace of aging did not depend on change in any 
particular lifestyle-influenced biomarker, such as rising body mass index [50]. 
 
The Dunedin cohort, having reached only the midpoint of the lifespan, lacked data to test 
whether the pace of aging measure predicts mortality. However, we were able to validate this 
measure in two ways. The first validation showed that study members who had been 
experiencing a more rapid biological pace of aging over the preceding 12 years had also reached 
an older estimated biological age in 2011-2012, when all cohort members were 38 years old [17]. 
For this analysis, we calculated for each study member a previously published 10-biomarker 
cross-sectional indicator of biological age [45, 51]. This biological-age indicator at age 38 years 
was a good validation benchmark because in NHANES participants aged 30 to 75 years, this 
cross-sectional indicator predicted mortality twenty years later, did so better than chronological 
age, and accounted for the association between chronological age and mortality [51]. As 
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hypothesized, the correlation between Study members’ pace of aging over the past 12 years and 
their attained biological age at the last followup was significant and moderate (Pearson 
correlation = .38).   
 
The second set of validation studies showed that individual differences in the biological pace of 
aging were significantly correlated, already by age 38, with diminished functional capacity, as 
would be expected in a gerontological study of older adults [17].  Study members with a more 
rapid pace of aging were less physically able: They had more difficulty than age peers with the 
Unipedal Stance Test of balance, the Grooved Pegboard Test of fine-motor coordination, and the 
Grip Strength test.  Study members with a more rapid pace of aging showed a decline in 
cognitive performance, net of their childhood baseline level on the same neuropsychological 
tests, and this was particularly true for tests of fluid intellectual abilities such as processing 
speed. Study members with a faster pace of biomarker aging also looked older according to an 
independent panel of raters who evaluated facial photographs of our Study members at age 38. 
These initial findings provide proof of principle that variation in the pace of aging can be 
quantified in young adults.  
 
What are the pressing research needs? We call for research on the pace of aging in other 
young cohorts to inform geroscientists about processes of aging in young humans, who are the 
eventual market for anti-aging therapies. The leap from healthy young lab animal to healthy 
young human may not be so simple. Humans’ aging is under more multi-factorial influence than 
lab animals’ aging and this heterogeneity is likely to complicate and even compromise clinical 
trial outcomes, but if we knew more about aging in young humans, trials could be planned to 
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maximize chances of success. Moreover, at present there is no outcome measure that can be used 
to show if a treatment has worked in young adults. Measuring aging in free-living humans early 
in their lifespans brings interesting new scientific opportunities and research needs, as noted 
below.  
 
First, there is a need for research to develop better, more reliable, valid and practical 
measurement technology to quantify the pace of aging in young adults. One obvious need is for 
more waves of biomarker data; quantifying the pace of aging will be enhanced with four or more 
biomarker data points [52]. In longitudinal panel studies, every additional wave of data increases 
the reliability and precision of measuring change and adds power. Moreover, four waves enhance 
capacity to test alternative functional forms of change. Another need is to know how far apart the 
waves must be to detect aging sensitively. Our waves were about 5 years apart, but shorter 
intervals should be tested [53].  Furthermore, research needs to evaluate the relative performance 
of biomarker subsets with the aim of identifying the most efficient “short-form” of the pace of 
aging that is most feasible. We used all 18 biomarkers that were repeatedly measured in the 
Dunedin Study, and our analyses showed that associations between pace of aging and validating 
measures of physical and cognitive functioning did not depend on any one biomarker [17]. 
However, other biomarkers that we did not have may be able to improve measurement, including 
repeated measures of physical function. Also, we weighted all biomarkers equally to 
transparently avoid assumptions, and to avoid a finding that was too cohort-specific. 
Nonetheless, another research need is to refine weightings of biomarker contributions to pace-of-
aging measurement. In fact, tests are needed of geroscience theory’s central claim that aging 
unites organ systems; are there systems that do not age in concert with others? The ultimate need 
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is to develop pace-of-aging measures that are good enough that they can be used to identify 
individuals who are most in need of intervention before clinical symptoms onset; i.e., young 
individuals who are already aging more rapidly than their age peers.  
 
Second, there is a need to find out how the pace of aging tracks over the entire life course. 
Studies tracking pace of aging earlier, in children, adolescents, and young adults, are needed to 
uncover when and how aging trajectories begin to diverge. For example, does rapid pace of 
aging bear any relation to early pubertal development? The ideal data-resource would comprise 
repeatable biomarkers that cover the entire life course validly, as has been reported for blood 
pressure [54].  Studies tracking pace of aging in midlife and older adults are also needed [55].  
Do individuals who age more rapidly in their twenties and thirties continue to age more rapidly 
onward through midlife and into late life? Preliminary evidence suggests they do; our pace-of-
aging measure correlated positively with a cross-sectional indicator of biological age [51] which 
has been reported to predict mortality better than does chronological age. However, cohort 
studies with late-life follow-up are needed to evaluate how well pace of aging in young adults 
forecasts their healthspan and lifespan.  
 
Third, there is a need to build an evidence base about what factors correlate with the pace of 
aging in young adults. Human aging has multifactorial origins. Therefore, to speed the 
development of novel intervention strategies it will be necessary to know what factors are 
creating the variation in young humans’ pace of aging. For example, cohort studies having 
repeated measures can test if within-individual change in the longitudinal pace of aging tracks 
 
 
Page | 16  
 
temporally alongside change in behavioral correlates (e.g., if depression remits, or physical 
activity improves, does the pace of aging slow?).  
 
Fourth, there is a need to test longitudinal repeated measures of the pace of aging against cross-
sectional genomic measures now being put forward, often referred to as genomic clocks [56-59]. 
Are these various measurements strongly correlated with each other and do they tap the same 
aging process?  If so, genomic clocks ought to predict: (a) each other, (b) chronological age, (c) 
mortality, (d) cognitive and physical function, and (e) deterioration in multiple organ systems over 
meaningful time spans: i.e., the measured pace of aging.  The genomic research agenda could 
also include studies that interrogate the pace of aging as a phenotype.  Genomic studies can 
search for profiles of gene methylation and expression of the pace of aging, not just 
chronological age, and genome-wide association studies can study the pace of aging, in addition 
to extreme-longevity.  
 
Fifth, because delayed aging is not necessarily the flipside of accelerated aging, researchers 
should additionally ask: What genomes and lifestyles characterize young adults who stay 
biologically young while their peers age? With good measurement of the pace of aging, such 
unusually resilient individuals can be identified for research while they are still young. Study of 
such individuals may reveal molecular and behavioral pathways to rejuvenation. 
 
Sixth, there is a need to develop measures of the pace of aging that are feasible for use as 
baseline and outcome criteria in future randomized clinical trials that will try to slow aging in 
humans. Pace of aging measures need to be good surrogates for late-life disease and mortality, 
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but feasible for use with trial participants for whom disease and death are far in the future. 
Practical measures of how fast a young clinical-trial participant is aging are needed to show  
which treatments work, and which do not, and for whom. For example, participants already 
aging slowly may have little room to improve in a therapeutic trial, whereas those aging most 
rapidly might be treatment-resistant.  
 
Why should young people’s pace of aging be on everyone’s mind? Currently, Western people 
live relatively healthy lives until their 60s, when morbidity starts to accumulate until death [60]. 
A nightmare scenario for population health is that death will be postponed to older and older 
ages, but morbidity will not [22]. The full nightmare will probably not happen, because there is 
evidence that healthspan has been extending [61]. Despite this evidence for compression of 
morbidity into older age groups, already the Global Burden of Disease Project found that 
compared to 1990, people in 2010 were living more years with disability from age-related 
conditions such as heart disease, type 2 diabetes, stroke, pulmonary disease, and dementia [1]. 
Treating these un-prevented diseases in late life has proven costly and largely ineffective, and 
consequently, effective strategies are needed to prevent age-related diseases before they onset. 
The goal, therefore, is not only to increase life expectancy but to ensure that added years at the 
end of life are healthy years of living and to improve the quality of longer lives [2]. To achieve 
this goal, morbidity needs to be postponed closer to death, that is, aging research must enable 
still-healthy young people to age more slowly and stay young longer.  It is now accepted that 
factors in early-life lead to age-related disease in later life but there is still a knowledge gap 
about the process of aging in between, and filling it will inform primary prevention. Studying 
aging as an antecedent cause of disease will become possible if researchers can quantify 
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differences among healthy individuals in their pace of aging. Moreover, the only way 
intervention researchers will know if trials have succeeded (or failed) to slow aging in young 
people is if they can accurately measure each young person’s pace of aging. Yet, most human 
geroscience omits young people. We look forward to a geroscience of the young.  
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